Recent Updates
Recently added Catalysts
STIM Positive Sentiment

Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business

Key Takeaway: Jorey Chernett, the largest independent shareholder of Neuronetics, has urged the Board to conduct a comprehensive review of strategic alternatives, including the potential sale of the TMS business. Chernett believes that separating the TMS and clinic businesses could unlock significant shareholder value, estimating a 5-7x increase in equity value. He emphasizes that the anticipated synergies from the merger have not been realized, and that a focused approach could enhance the clinic business's performance.
Price reaction · baseline $1.52 (2026-04-02 close) · 2 other STIM headline(s) in the window, move may be shared
day 0 close · peak
+15.8%
day 1
+3.9%
day 3
-9.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Potential for 5-7x upside for shareholders through strategic review.
  • High-quality assets with expanding total addressable markets.
  • Opportunity for enhanced focus on the clinic business.

CONCERNS & RISKS

  • Synergies from combining TMS and Greenbrook have not materialized.
  • STIM has underperformed compared to peers since acquisition.
  • Resource limitations hinder effective management of distinct businesses.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~57 mo
Minimal dilution risk
Lead asset
Repetitive Transcranial Magnetic Stimulation
Phase 3 · Major Depressive Disorder

Full Press Release Details

Delivers Letter to STIM Board Outlining Potential 5-7x Upside for Shareholders Inherent in Sale of TMS and Standalone Clinic Business
BLOOMFIELD HILLS, Mich.,April 6, 2026/PRNewswire/ -- Jorey Chernett, the largest independent shareholder of Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") owning approximately 14.12% of outstanding shares, today delivered a letter to the STIM Board of Directors (the "Board") calling for the immediate initiation of a comprehensive review of strategic alternatives, including the potential sale of the Company's TMS business.
The letter outlines the substantial value that could be delivered to shareholders if a sale of the TMS business were to be executed and the clinic business was to operate on a standalone basis. Specifically:
The letter outlines the substantial value that could be delivered to shareholders if a sale of the TMS business were to be executed and the clinic business was to operate on a standalone basis. Specifically:
• STIM has two compelling, high-quality assets with large and expanding TAMs, market-leading positions, accelerating adoption, and meaningful industry tailwinds.
• Despite these attractive businesses, the anticipated synergies of combining TMS and Greenbrook have not materialized, and the premise of 1 + 1 > 3 has proven illusory.
• Since the December 2024 acquisition, pure-play peers have dramatically outperformed STIM and now trade at substantially higher multiples.
• A micro-cap enterprise with finite resources cannot effectively serve two structurally distinct businesses.
• Applying conservative, yet comparable multiples to STIM's constituent businesses implies equity value to shareholders of 5–7x the current price of STIM's stock.
• Further upside could be present with effective oversight and full dedication of resources to the industry leading clinic business.
• The Board must act in the best interest of STIM shareholders and immediately engage qualified advisors to evaluate all strategic alternatives.
The full text of the letter can be foundhere:

Media Contact:ASC AdvisorsTaylor Ingraham / Max Rayden[email protected]/[email protected]203 992 1230

Frequently Asked Questions

What did Jorey Chernett propose to the STIM Board?

Chernett proposed a comprehensive review of strategic alternatives, including the sale of the TMS business.

What potential upside did Chernett mention for shareholders?

He mentioned a potential 5-7x upside in equity value for shareholders if the TMS business is sold.

Why does Chernett believe the merger has not worked?

He believes the anticipated synergies from combining TMS and Greenbrook have not materialized.

What does Chernett suggest for the clinic business?

He suggests that the clinic business should operate independently for better focus and performance.

Last updated: Apr 6, 2026